Edoxaban
Edoxaban is the medicine inside Savaysa, a blood thinner taken by mouth. The US label says it is a factor Xa inhibitor approved to cut the chance of stroke and of clots elsewhere in the body in people with nonvalvular atrial fibrillation, and to treat deep vein thrombosis and pulmonary embolism after 5 to 10 days of initial treatment with a parenteral anticoagulant. For the atrial fibrillation use, the label says it should not be used in people with a creatinine clearance above 95 mL/min, because of more ischemic strokes than with warfarin at the highest dose studied.
Also called Savaysa
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 1599538. The openFDA record for NDA 206316 names Daiichi Sankyo as sponsor of the brand Savaysa and lists the original submission as approved on 2015-01-08; the label read here is effective 2025-07-10. A selective factor Xa inhibitor per the label. The claim on this page holds the indications.
Trials at a glance
The figures count the 18 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 18
- Phase 3 or 4
- 14
- Recruiting
- 1
- Regulatory decisions
- 0
| Phase | Recruiting | Not yet recruiting | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|---|---|
| Phase 2 | 0 | 0 | 1 | 0 | 1 | 2 |
| Phase 2/3 | 0 | 1 | 0 | 0 | 1 | 2 |
| Phase 3 | 0 | 0 | 7 | 1 | 2 | 10 |
| Phase 4 | 1 | 1 | 2 | 0 | 0 | 4 |
| All phases | 1 | 2 | 10 | 1 | 4 | 18 |
Conditions these trials study
- Arrhythmia (heart rhythm problems)
- Atrial fibrillation (AF)
- Stroke
- Deep vein thrombosis
- Heart valve disease
- Pulmonary embolism
- Aortic stenosis
- Ischemic stroke
- Atrial flutter
- Cerebral small vessel disease
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- A selective inhibitor of factor Xa (US drug label).
Claims and evidence
Context People with nonvalvular atrial fibrillation, or with deep vein thrombosis or pulmonary embolism after initial therapy (US label of SAVAYSA, edoxaban)
- Recipient
- Recipient not specified
- Population
- People with nonvalvular atrial fibrillation, and people with deep vein thrombosis or pulmonary embolism who have had 5 to 10 days of initial therapy with a parenteral anticoagulant, restated from the label indications. Other sections of the label were not read.
- Care setting
- Not stated in the label passages read
- Geography
- United States (label as published through FDA and openFDA)
- Life stage
- Not stated in the label passages read (they say patients and give no age)
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (regulatory label)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
The openFDA record for NDA 206316 names Daiichi Sankyo as the sponsor of SAVAYSA (edoxaban tosylate) and lists an original submission, number 1, as approved on 8 January 2015, in the class Type 1 - New Molecular Entity. The label text read here, effective 10 July 2025, says SAVAYSA is a factor Xa inhibitor with two uses: cutting the risk of both stroke and systemic embolism when nonvalvular atrial fibrillation is present, and treating deep vein thrombosis and pulmonary embolism following 5 to 10 days of initial therapy with a parenteral anticoagulant. For the atrial fibrillation use, the label says it should not be used in patients with a creatinine clearance above 95 mL/min because of an increased risk of ischemic stroke compared with warfarin at the highest dose studied.
Applies to Recipient not specified People with nonvalvular atrial fibrillation, or with deep vein thrombosis or pulmonary embolism after initial therapy (US label of SAVAYSA, edoxaban)
- Certainty method
- Not assessed
- Limitations
- The label and the openFDA record state what FDA has authorized and how the label words it, not how well the medicine works for any person. openFDA data are unvalidated. Only the indications and mechanism passages of the label were read; doses, contraindications and warnings are not described here, and later label changes are not covered.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (7)
-
Supports FDA drug application NDA206316 (openFDA Drugs@FDA record)
- Locator
- results[0].application_number
- How it applies
- Quote from the FDA record.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
8b981b3259f7dac7e80f9cd13aa50f5bc729249572085f8bcf4b24a0f1f60d5b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository. It includes product-code and package fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA206316 (openFDA Drugs@FDA record)
- Locator
- results[0].sponsor_name
- How it applies
- Quote from the FDA record.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
8b981b3259f7dac7e80f9cd13aa50f5bc729249572085f8bcf4b24a0f1f60d5b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository. It includes product-code and package fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA206316 (openFDA Drugs@FDA record)
- Locator
- results[0].submissions[6].submission_status_date
- How it applies
- Quote from the FDA record: date of the approved original submission.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
8b981b3259f7dac7e80f9cd13aa50f5bc729249572085f8bcf4b24a0f1f60d5b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository. It includes product-code and package fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA206316 (openFDA Drugs@FDA record)
- Locator
- results[0].submissions[6].submission_class_code_description
- How it applies
- Quote from the FDA record.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
8b981b3259f7dac7e80f9cd13aa50f5bc729249572085f8bcf4b24a0f1f60d5b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository. It includes product-code and package fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA206316 (openFDA Drugs@FDA record)
- Locator
- results[0].submissions[6].submission_status
- How it applies
- Quote from the FDA record: AP is the approved status.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
8b981b3259f7dac7e80f9cd13aa50f5bc729249572085f8bcf4b24a0f1f60d5b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository. It includes product-code and package fields that FDA publishes; records here do not repeat them.
-
Supports SAVAYSA drug label (openFDA record, set id e77d3400-56ad-11e3-949a-0800200c9a66)
- Locator
- results[0].indications_and_usage[0]
- How it applies
- Quote from the label: the indications and the limitation of use.
- Retrieved
- Source effective date
- 2025-07-10
- Source state
- Current
- Version fingerprint
a28b87c253a1cdabc0bab935072a07917d894b9651865db276f06dc2e49ccbff- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw file is committed in the atlas repository. A second copy was fetched 2026-11-09; its bytes differ from the 2026-10-30 copy. The 2026-11-09 copy is committed in the atlas repository.
-
Supports SAVAYSA drug label (openFDA record, set id e77d3400-56ad-11e3-949a-0800200c9a66)
- Locator
- results[0].openfda.brand_name[0]
- How it applies
- Quote from the label record.
- Retrieved
- Source effective date
- 2025-07-10
- Source state
- Current
- Version fingerprint
a28b87c253a1cdabc0bab935072a07917d894b9651865db276f06dc2e49ccbff- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw file is committed in the atlas repository. A second copy was fetched 2026-11-09; its bytes differ from the 2026-10-30 copy. The 2026-11-09 copy is committed in the atlas repository.
FDA label
Assembled by a program from the openFDA drug label dataset, retrieved 8 November 2026, for the products that contain this drug: the label of the application holder or its company group, never a repackager's. Data provided by the U.S. Food and Drug Administration (open.fda.gov). The label is a manufacturer's submission that FDA has not verified, and the label on the product may differ. 1 label below.
SAVAYSA
- Application
- NDA206316
- Labeler
- Daiichi Sankyo Inc.
- Label version
- Version 28, effective
- Label set id
e77d3400-56ad-11e3-949a-0800200c9a66- Boxed warning
- Yes
- Sections the label has
- Indications and usage Contraindications Warnings and cautions Adverse reactions Drug interactions Use in specific populations Pregnancy Pediatric use Geriatric use Clinical pharmacology Clinical studies
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 1
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 4 efficacy supplement approvals on record.
Registry trials 18
Record details
- Record id
cardio:edoxaban- Content hash
2991ce8be149c6d685bc700b8fe14b43a0f9b2e7c1d970a4a7438c0e0578ce74